scispace - formally typeset
K

Katarzyna Pawinska-Wasikowska

Researcher at Jagiellonian University Medical College

Publications -  20
Citations -  228

Katarzyna Pawinska-Wasikowska is an academic researcher from Jagiellonian University Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 13 publications receiving 83 citations. Previous affiliations of Katarzyna Pawinska-Wasikowska include Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Global Retinoblastoma Presentation and Analysis by National Income Level

Ido Didi Fabian, +476 more
- 01 May 2020 - 
TL;DR: This cross-sectional analysis reports the retinoblastoma stage at diagnosis across the world during a single year, investigates associations between clinical variables and national income level, and investigates risk factors for advanced disease at diagnosis.
Journal ArticleDOI

Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries

Ido Didi Fabian, +203 more
TL;DR: Fewer than half the expected number of patients with retinoblastoma presented to African referral centres in 2017, suggesting poor awareness or other barriers to access, despite the relatively shorter distance travelled by African patients, they presented with later-stage disease.
Journal ArticleDOI

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

TL;DR: In this article, guidelines for adjuvant treatment in European retinoblastoma referral centers were collected in an online survey among all members of the European Retinoblasoma Group (EURbG) network.
Journal ArticleDOI

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia

TL;DR: This is the first retrospective study from Poland on efficacy and toxicity of blinatumomab therapy in children with r/r ALL and clearly showed blinumomab as not only a feasible but also an effective therapeutic option in pretreated children withR/r BCP-ALL, with a tolerable toxicity profile, paving the way for an HSCT procedure.